Forest Laboratories Inc

Forest Laboratories — Proxy Contest (August 2011)

66 slides from Forest Laboratories's proxy contest presentation, Aug 9, 2011

  1. Slide 1: Schedule 14A Proxy Statement - Forest Laboratories, Inc.

    SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted

  2. Slide 2: Filing fee and prior filing information

    4) Proposed maximum aggregate value of transaction: 5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the pre

  3. Slide 3: Fix Forest Laboratories website and proxy statement legend

    The Icahn Group has launched a website entitled “Fix Forest Laboratories” – http://www.fixforest.com/ ON JULY 19, 2011, THE PARTICIPANTS (AS DEFINED BELOW) FILED A DEFINITIVE PROXY STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION. SECURITY HOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEM

  4. Slide 4: FixForest.com disclaimer

    Viewer FIX This Disclaimer: the information Many such Sections Amylin However, addition, ON HOLDERS ALEXANDER FUND CORP., CORP. BECAUSE PROXY SECURITIES NUMBERS: OTHER PREVIOUSLY ENTER Copyright accuracy JULY FOREST website beliefs. ofLP, (COLLECTIVELY, Logout ICAHN Pharmaceuticals, WEBSITE THAN IS

  5. Slide 5: Fix Forest Laboratories needs to successfully navigate challenges

    Viewer FIX Help -Lexapro -Government -Current Forest -Icahn FOREST usLabs Laboratories nominees representation Logout Fix directors andForest needs sought Namenda LABORATORIES have have independent Laboratories… needs to will succeeded not exclude patent benefit the recognized Icahn expirations and

  6. Slide 6: Forest Labs lost $17B in value versus peers

    0-Forest 50 100 150% FRX 103% 52% 50% 47% 34% -65% -100 Change Note: Source: Support >50 Click WPI Change Labs here Public in TheCEPH value lost to Icahn indocuments start value, % ($B) value ENDP Nominees by-$17B represents while examining MYL $2B peers and AGN$2B change Vote Forest gained $1B Thei

  7. Slide 7: Lexapro and Namenda patent expirations put sales at risk

    Viewer FIX -SG&A This Lexapro Currently, ButFOREST the will expenses Logout Lexapro and is push Selling, 55% LABORATORIES Namenda SG&A will of patent General FY11 beexpenses challenged patent expiration product & Administrative expirations well sales, will byoutside Lexapro immediately patent place

  8. Slide 8: Lexapro and Namenda patent expirations present significant headwinds to sales

    Lexapro 0$Annual 1,000 2,000 3,000 4,000 $5,000M Other FY11A 4,213M Lexapro Lexapro product and -$2,038M Namenda Lexapro sales patent $1,045M ($M) patent expiration Other $3,220M expirations Other Growthpresent in Othersignificant Products FY13E headwinds

  9. Slide 9: Operating profit decline from patent expirations

    0$Annual 500 1,000 $1,500M FY11A $252M -$1,144M Lexapro FY13E 1,396MLexapro operating and Namenda patent profitpatent expiration ($M) expirations and Other Product growth

  10. Slide 10: Lexapro patent expiration risk and sources

    place Note: Source: > Copyright Next: 85% Fiscal Analyst Department ©ofyear 2011, netresearch; sales ends FixForest.com. of March at Health risk Public 31; & documents Human Lexapro All rights Services 55%reserved. of sought FY11Please product to ban seeCEO sales, important Howard patent disclaimers

  11. Slide 11: HHS sought to ban CEO Solomon from federal healthcare programs

    Viewer FIX -Department in criminal FOREST Logout penalties. ofLABORATORIES Health & Human Services sought to ban CEO Howard Solomon from participating in federal healthcare programs after paying $313 Million in settlement costs, including $164 Million

  12. Slide 12: Management and government actions and litigation

    Management DoJ Subsidiary As Received Health Department Various Defendants State Currently Defending Defendant Entered duties Publicly NYSE Forest Note: Source: > Next: a –result, & DoJ USAtty connected Labs Agencies Federal Over Public government into reprimanded subpoena defending –in class pled F

  13. Slide 13: Succession concerns after President and COO departure

    Viewer -FIX The Many FOREST recent Logout investors departure LABORATORIES are concerned of President by David and COO Solomon’s has led to recent CEOpromotion Howard Solomon taking on added responsibilities of President. Company has not publicity announced any succession plan

  14. Slide 14: Management succession and tenure

    Board Many Marketing/Commercial CFO COO President CEO Position Scientific Corporate Kenneth John Lawrence Office Howard ?F Elaine Marco David Recent > rancis Next: Eggers investors responsible Solomon Holder Hockberg Taglietti departure Perier Over Solomon Goodman & Affairs/R&D Olanoff Development C

  15. Slide 15: Over 90% of revenue from one therapeutic area

    Viewer -FIX This Over FOREST is90% Logout alsoofthe LABORATORIES allarea revenue where comes patents from willjust expire one therapeutic on two critical area, drugs Central in the Nervous next 4 System years drugs

  16. Slide 16: Scattered efforts across therapeutic areas

    Scattered SCATTERED Gastro-enterology Central Lexapro Namenda Savella Cariprazine Bystolic Cardio-vascular Azimilide Apadenoson Teflaro Anti-Infective Celtazikline Avibactam Armour Endocrinology TTP399 Thyrolar Levothroid OB Pain Cervidil Combunox GRT Aclidium Daliresp Aerobid Respiratory LAS Note:

  17. Slide 17: SG&A compared with specialty pharma

    Note: Source: > Copyright Next: ($M) While Public ©represents 2011, SG&A documents FixForest.com. against FY 2011 Specialty sales Allending rights PharmaMarch reserved. is in31 line Please or today… (current see important state of development) disclaimers under LEGAL link.

  18. Slide 18: SG&A in line with specialty pharma peers

    Viewer -FIX Forest FOREST Logout Labs SG&A LABORATORIES spending is currently in line with it’s Specialty Pharma peer group

  19. Slide 19: SG&A as percent of sales versus specialty pharma

    Currently, 2010 50% 40% AGN Note: FRX=Forest Source: >And Copyright 40 39% SG&A SHP FRX SG&A Analyst 3037% Forest © WCRX 20 represents % Labs, 2011, against 10 34% of research; Labs 0net VRX=Veleant CEPH FixForest.com. 31% Big sales FY11 SG&A Pharma 30% Public ENDP ending spending 20% documents FRX

  20. Slide 20: SG&A versus Big Pharma peers

    Viewer -FIX Similar 2010 35% 31% NVS Note: MRK=Merck, Source:Analyst >The SG&A FOREST 30 31% SG&A LLY Lexapro FRX Logout situation 25 also 30% AZN 20 represents margin inLABORATORIES 15 AABT=Abbot patent 30% research; line BAY when 10 compared % 30% 5expiration FRX FY11 0Forest Public 30% GSK ending

  21. Slide 21: Lexapro patent expiration will severely impact the rest of Forest

    Viewer FIX Lexapro -in -Without FY11, FOREST Logout Patent Lexapro, Lexapro LABORATORIES Expiration SG&A R&D operating accounts expense expense Will for margin Severly virtually would would would Impact increase all increase decrease of Forest’s The from from Rest from 14% operating 30% Of 33% to Fo

  22. Slide 22: Without Lexapro, operating margin falls

    Lexapro FY2011 Net Cost COGS SG&A R&D Operating Note: other Source: > Next: sales of income 600 % COGS % 1,254 goods And Analyst FRX of patent ($M) of 0margin Expenses Income sales 600 sales these allocated 394 -Lexapro $964 $4,213 expiration research; 14% 859 23% % 30% $1,396 problems $530 $2,817 3

  23. Slide 23: Excluding Lexapro, SG&A soars versus specialty pharma

    Viewer -FIX Excluding 2010 50% 45% FRX Note: Source: > But Next: FOREST 40 40% AGN SG&A excluding FRX Logout Analyst Without 3039% Lexapro, SHP 20 excludes %LABORATORIES 10 37% of Lexapro, WCRX research; Lexapro 0netForest 34% Lexapro sales CEPH Forest revenue, 31% Public Labs making 20% ENDP Labs s

  24. Slide 24: Without Lexapro revenue, SG&A soars vs Big Pharma

    >Next: Without Copyright © 2011, Lexapro FixForest.com. revenue, Forest All rights Labsreserved. SG&A soars Please compared see important to Bigdisclaimers Pharma peers under LEGAL link.

  25. Slide 25: Without Lexapro revenue, SG&A soars vs Big Pharma

    FIX Logout -Viewer Without FOREST Lexapro LABORATORIES revenue, Forest Labs SG&A soars compared to Big Pharma peers

  26. Slide 26: Similar situation at Big Pharma peers

    Similar 2010 50% 45% FRX Note: Source: >Next: Copyright 40 31% NVS SG&A FRX Change situation Analyst 3031% ©LLY 20 excludes margin 2011, 10 30% is AZN research; as 0needed FixForest.com. Forest % 30% Lexapro BAYat 30% Public Labs GSK FRX... making 29% spends PFE documents All Market 28% MRK same rig

  27. Slide 27: Competitors gained value while Forest lost 65%

    Viewer FIX Average In -Competitors While Allergan Watson Mylan Cephalon Endo That FOREST Forest increased Time Logout increased Tenure increased has increased have shrinks Forest’s LABORATORIES increased Of from fared from from Forest’s in from Market $2.9B value, much $6.7B in $5.0B $3.5B value New

  28. Slide 28: Market value destroyed over last 7 years

    Value Equity $30B $26.6B $9.3B FRX $4.3B $2.9B $5.2B $3.5B $6.8B $5.0B $10.1B $6.7B $22.4B $11.0B Change Note: Source: > Next: AGN 20 Market destroyed March value March Forest Public in10value MYL 0($B) 2011 cap. 2004 lost documents over -$17.3B WPI =value market market average last CEPHwhile $11.4B

  29. Slide 29: CEO Solomon's compensation not tied to share performance

    ForestWPI 150% -65% FRX Change Note: Source: >Next:34% Change 100 Labs CEO Public in CEPH value 50 47% lost Solomon’s 0indocuments -50 50% value % ($B) value ENDP -100 52% -$17B while represents compensation MYL 103% peers $2B AGN$2B change gained $1B notin substantial tied $3B market to$11B share c

  30. Slide 30: CEO compensation versus equity value decline

    Viewer -FIX Chairman $10M $9.0M Other FY While Note: Source: While 2004 FOREST Fiscal Options 8Forest $7.0M Logout Forest Public 6FY 4& and 2year CEO 2005 Labs 0$6.7M LABORATORIES CEO Stock Labs documents ends Solomon FY equity Solomon equity Bonus $5.4M 2006 March value value FY Salary compensation

  31. Slide 31: Current directors lack independence

    >Next: Current Copyright © 2011, directors FixForest.com. lack independence... All rights reserved. Please see important disclaimers under LEGAL link.

  32. Slide 32: Directors lacked independence and experience

    Viewer FIX Forest FOREST directors LogoutLABORATORIES lacked independence and experience prior to Icahn campaign… and acknowledged this by replacing two of the four longest directors with no relevant experience

  33. Slide 33: Prior and current directors, tenure and background

    PriorGoldwasser Name Howard Lawrence Nesli William George Dan Kenneth Lester Peter Associate Forest Note: Assumes >Next:to Zlmetbaum Basgoz *Inside Tenure Salans Labs These Cohan Icahn Solomon Candee Goodman payment Professor, Olanoff acknowledged 513 (year director campaign, 34 (2006) 52 (1998) 34

  34. Slide 34: Replacing four directors with Icahn nominees

    Viewer -FIX Replacing FOREST Logout Directors LABORATORIES Solomon, Goldwasser, Goodman, and Salans with Icahn nominees will provide fresh perspective, independence, operational expertise, and highly relevant board experience

  35. Slide 35: Reasons to replace Solomon, Goldwasser, Goodman, Salans

    However, Howard Director Dan Kenneth Lester Reason OIG-HHS Multiple Responsible Length Former No Icahn Next: operational other Goldwasser nominees Current Salans of reporting to Solomon Goodman adverse recent more tenure Replace sought for Board experience director public will company’s (47 (34 civi

  36. Slide 36: Current board is not receptive to change

    Viewer -FIX TheFOREST current Logoutboard LABORATORIES has demonstrated it is not receptive to change by making the following statements about the Icahn Nominees

  37. Slide 37: Board statements versus facts

    Current “Forest’s “Mr. Howard Forest Facts Alex Board’s Source: >Next: Copyright Icahn’s Denner Board CEO board Forest “careful” Solomon, Board © nominees Solomon 2011. and Statement has not Labs has not Richard review receptive Chairman FixForest.com. carefully letter interviewed has bring and Mull

  38. Slide 38: CEO Solomon reduced ownership by 75%

    - CEO Chairman 20M 15M 2003 $600M $490M Sale Solomon Note: >Next: Copyright Tax 15 13M 2004 Tax Solomon Icahn 400 $42M 10 Gift shares reduced represents and 11M ©2005 5200 2011. 0parties Total $22M CEO 11M owned 0has 2006 ownership FixForest.com. Solomon’s reduced $554M are 6M stock 2007 ($M) much 7

  39. Slide 39: Icahn Parties much more aligned with shareholders

    - The FRX 50% 10 15 20M Icahn 7.2% All 3.5M Note: 1.3% shares >Next: ofother o/s shares 3.6M Icahn parties Parties Howard includes Meet shares directors Parties owned the much Solomon’s 2.0M Icahn and own more (M) options executives Nominees… 19.9M 7.2% aligned 3.5MSource: ofshares all with Howard F

  40. Slide 40: Icahn nominees: Alexander Denner

    Viewer FIX The Alexander -Key Managing Current Former Icahn FOREST Qualifications: Logout director director Nominees Denner Director, LABORATORIES at at ImClone Biogen Will IcahnLeverage Partners Idec, Systems, Amylin Significant Adventrx Pharmaceuticals, Experience Pharmaceuticals Enzon To Benefit

  41. Slide 41: Icahn nominees: Richard Mulligan and Eric Ende

    Richard Eric -Key Mallinckrodt Co-founder, Current Former Ende Qualifications: Mulligan senior director director Silverback Professor biotechnology at at Genzyme ImClone Biogen Mesaof Group Therapeutics, Genetics, Idec, Systems, andEnzon specialty Harvard Somatix ALEA Pharmaceuticals, pharma Medical

  42. Slide 42: Icahn nominees: Lucian Bebchuk

    Lucian -Key >Next: Copyright William Renowned Current Qualifications: Bebchuk Indirector Friedman service © corporate 2011,to atFixForest.com. and OJSC other governance Alicia Biopharma MMC Townsend Norilsk expert Allcompanies, rights Nickel Friedman reserved. theProfessor Icahn Please nominees see

  43. Slide 43: Icahn nominees help create value for all shareholders

    Viewer FIX Icahn In service FOREST Nominees Logout to other LABORATORIES OnBiopharma Biopharmacompanies, Boards Help theCreate Icahn nominees Value Forhave All Shareholders: created share price appreciation ranging from 14% to 102%, in a very short period of time… from 10 to 31 months after election

  44. Slide 44: Share price appreciation after nominees were elected

    01Share 25 50 75 100 125% Months BIIB IMCL GENZ ENZN AMLN 102% 97% 42% Note 31 10 26 Pharmaceuticals. Source: Next: Copyright 4% Share Bebchuk’s price Public to © realize once appreciation 2011 documents appreciation experience GENZ-Genzyme. FixForest.com. % inrepresents governance, All BIIB rights

  45. Slide 45: Bebchuk uniquely suited to join Forest's board

    Viewer -FIX LABORATORIES Bebchuk’s FOREST Logout experience in governance, law, and compensation make him uniquely suited to join Forest’s board

  46. Slide 46: Bebchuk's experience addresses board issues

    Issue Lack Nomination Lead Myriad Flawed Place Program to Relevant Bebchuk’s structures, Legal Bebchuk A “Paying Next: Copyright leading performance of director at Bebchuk Ende’s expertise legal pay Forest adequate for Experience served authority ©succession background experiences Long-Term arrangem

  47. Slide 47: Ende's Genzyme experience relevant at Forest Labs

    FIX Viewer -LABORATORIES Ende’s FOREST Logout Genzyme experience will be highly relevant at Forest Labs

  48. Slide 48: Ende's experience addresses board issues

    IssueOversight Entrenched Negative Myriad Lack Unproven Potential Hold Initiation Evaluate Independent Relevant Board Helped Audit Risk Ende >Next: Copyright of Forest will worked helped evaluated atCommittee contained Ende’s re-focus legal Forest focus Forest each GENZ Solution operating and add bu

  49. Slide 49: Ende's experience as analyst, doctor and director

    Viewer FIX LABORATORIES -During Ende Ende’s Acquisitions Ende’s Financial Corporate Operating Clinical Drug Competitive Licensing FOREST worked understands markets experience experiences that Logout experience data statements opportunities leverage governance time, as landscape and aEnde senior what

  50. Slide 50: Denner and Mulligan drove change at ImClone

    >Next: Nominees Copyright © 2011.Denner FixForest.com. and Mulligan All rights drovereserved. substantial Please change see at important ImClonedisclaimers Systems across underPartner LEGAL Relations, link. Cost Structure, Product Pipeline. Culture, and Litigation...

  51. Slide 51: Denner and Mulligan drove change at ImClone Systems

    Viewer -FIX LABORATORIES Nominees FOREST Logout Denner and Mulligan drove substantial change at ImClone Systems across Partner Relations, Cost Structure, Product Pipeline, Culture, and Litigation…

  52. Slide 52: ImClone changes: partners, costs, pipeline, culture, litigation

    Denner Partner Recharged Initiated From Cost Margin Increased Product Industry Exec. Significantly Cancelled Pipeline ImClone Culture Took Settled Litigation Removed Source: >Next:Structure steps 2005 Committee The litigation Relations expansion and Public Pipeline cited dialogue, had cost morale sp

  53. Slide 53: Denner at Biogen Idec

    Viewer FIX Icahn LABORATORIES -dramatic >Next: margin Copyright Alex Worked Partnered Collaborated Board FOREST Nominees Denner At expansion Logout empowered acceleration together Biogen ©with 2011. and with existing Collaborated and Idec, with Richard FixForest.com. existing management of significa

  54. Slide 54: Denner and Mulligan at Biogen Idec

    Viewer -FIX LABORATORIES expansion Icahn Alex Partnered Collaborated acceleration Worked Board Source: At Biogen FOREST Denner nominees empowered Logout Public together with and Idec, of and with significant existing documents clinical collaborated with Richard Denner existing management existing ac

  55. Slide 55: Icahn nominees worked with existing directors to drive change

    >Next: The©Icahn Copyright 2011,Nominees FixForest.com. WorkedAllWith rights Existing reserved. Directors Please To seeDrive important Substantial disclaimers Change under At Several LEGALBiopharmas: link.

  56. Slide 56: Change at Genzyme, Enzon and Amylin

    Viewer FIX -TheFOREST Icahn Logout nominees LABORATORIES worked with existing directors to drive substantial change at Genzyme, Enzon, and Amlyn...

  57. Slide 57: Changes at Amylin, Enzon and Genzyme

    Icahnpharmaceutical Other R&D Operational Amylin Enzon Genzyme Examined Executed Reprioritized Sold Declassified Reorganized Reduced Focused Source: >Next: company nominees With Public R&D overhead spending three multiple board our commercialization and efforts documents business worked past advance

  58. Slide 58: Icahn nominees will seek to enhance value

    Viewer FIX Icahn -Value: >Next: Copyright Accelerate Focus Examine Share Ensure Maximize FOREST Nominees Icahn best Logout company investor © cost return practices development 2011, nominees LABORATORIES structure Have interests on of FixForest.com. strategic capital from Several will and and repres

  59. Slide 59: Voting instructions for street-name holders

    Viewer FIX Street-Name If two Internet: 1. Telephone: 2. 3. you Gomethods: Please Enter Follow FOREST to hold Logout your the call the your Web Holders: the 12-digit instructions LABORATORIES shares toll-free site www.proxvvote.com. Control though telephone provided. Number a custodian number locate

  60. Slide 60: Voting instructions for registered holders

    Registered If Internet: 1. Telephone: 2. 3. Copyright you Go to Please Enter Follow areyour the call the a© Holders: registered Web 2011, toll-free Control instructions site: FixForest.com. Number https://www.directvote.com/fbx. 1-888-216-1292. nameprovided. shareholder, located All on rights you th

  61. Slide 61: WSJ: Court gives Icahn ammo against Forest

    Viewer FIX WSJ: Aug042011 Forest Thursday A drug Please *Copyright Consent Delaware judge FOREST company’s Court Labs* click Logout this August of ©Gives court here week 2011. the LABORATORIES stock, author for 4, agreed said Carl FixForest.com. 2011 therequested Icahn’s Icahn and full to Atprovide

  62. Slide 62: Bloomberg: Court gives Icahn ammo against Forest

    Court By Bloomberg A drug Delaware judge Shira company’s Gives this Ovide News court week Carlstock, Icahn agreed said requested Icahn’s Ammo to provide firm Against thecan Carl minutes Forest access IcahnasLabs minutes some part of potential his fromeffort a ammunition Forest to unseat Labs four bo

  63. Slide 63: Icahn's effort to exclude Solomon and HHS case

    Icahn’s Medicare the If effort Herschel In It’s candidates, HHS amarketing-misconduct not recent toclear case decides exclude Weinstein and investor according against what Medicaid, toSolomon the exclude presentation, told the to Forest company The aover person from case. Solomon Wall Labs alleged g

  64. Slide 64: FixForest.com disclaimer

    Viewer FIX This Disclaimer: the information Many such Sections Amylin However, addition, ON HOLDERS ALEXANDER FUND CORP., CORP. BECAUSE PROXY SECURITIES accuracy JULY FOREST website beliefs. ofLP, (COLLECTIVELY, Logout ICAHN Pharmaceuticals, IS of the we their 19, ICAHN AVAILABLE this THEY ARE on st

  65. Slide 65: D.F. King contact and website copyright

    D.F. KING (212) OTHER PREVIOUSLY Copyright 269-5550. THAN ©&2011, CO., PUBLISHED ASFixForest.com INC. EXPRESSLY BY TELEPHONE MATERIAL All INDICATED rightsINCLUDED AT reserved. THE OTHERWISE FOLLOWING Please ON THIS seeON important WEBSITE THIS NUMBERS: WEBSITE, disclaimers AS STOCKHOLDERS PROXY CONS

  66. Slide 66: Vote the Icahn Gold Card

    Fixhelp Vote to FixForest.com Forest thenavigate Icahn Laboratories: Gold challenges… Card nominees

Forest Laboratories — Proxy Contest (August 2011) on 6ix